How does the EU HTA Regulation affect my market access strategy?
Answers from the sources
regenold GmbH
“The EU HTA Regulation introduced Joint Clinical Assessments (JCAs) that produce EU-wide clinical evidence evaluations. Since January 2025, JCAs apply to new oncology products and ATMPs.”
Sourceregenold.com
Continue exploring
About these subjects
Related reading
- How do I handle informed consent under both the CTR and GDPR?
- What should we be ready to show in an inspection?
- What happens when my EDC or safety database provider has servers outside the EU?
- Do I need a DPO for my clinical trial?
- How has ICH E6(R3) changed how you design trials?
- Do we need documentation if AI is "just drafting"?
- How quickly can you mobilise a DD team?
- Do you work on both buy-side and sell-side mandates?
- What does it mean when you “act as sponsor” for an EU clinical trial?
- What is the difference between an EU sponsor and an EU legal representative?
- How do we qualify a vendor AI tool?
- Do you handle HTA dossiers and pricing negotiations directly?
- Do you support ISO 27001 certification, and are you certified yourselves?
- What is the difference between a site visit during DD and a formal GMP audit?
- How do you coordinate between the regulatory submission and market entry?
- What market entry infrastructure can you provide directly?
- What happens if data is incomplete or access is restricted during the process?
- regenold GmbH — company guide
Data formats and record details
Download this recordapplication/json
- Surface ID
- urn:readyscan:corpus:buyer-question:regenold-gmbh-q140571087-answer-4591d5048634f515fd4b
- Material fingerprint
- fnv1a64:4751682e567f095c
- Membership fingerprint
- fnv1a64:ebfa9a6744ac32d8
- Published
- 2026-10-26
- Modified
- 2026-10-26
- ready-scan-subjects/Q140571087
- revision Q140571087:content:42d5154a2e8358d1